Comparative Pharmacology
Head-to-head clinical analysis: DARVON versus ZIPAN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON versus ZIPAN 50.
DARVON vs ZIPAN-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
ZIPAN-50 (zinc acetate) is a dietary supplement that provides zinc, an essential trace element. Zinc acts as a cofactor for numerous enzymes, including those involved in DNA synthesis, cell division, and immune function. It also stabilizes cell membranes and has antioxidant properties.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
50 mg orally once daily
None Documented
None Documented
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Terminal elimination half-life is 4 hours (range 3-5 hours) in patients with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Renal excretion of unchanged drug accounts for approximately 60%, with 30% as glucuronide conjugate. Biliary/fecal elimination contributes 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic